Bright Minds Biosciences (DRUG) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Evotec (EVO) over the past year, losing 12.0% versus a loss of 61.2%. Over five years, DRUG leads with a +45.5% price change compared with -93.2% for EVO. Evotec is the larger company by market cap ($543.7 million vs $533.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | EVO |
|---|---|---|
| Share price | $54.05 | $1.53 |
| Market cap | $533.15M | $543.75M |
| 1-day change | +3.94% | -2.55% |
| YTD return | -30.74% | -50.32% |
| 1-year return | -11.99% | -61.17% |
| 5-year return | +45.49% | -93.23% |
| EPS (TTM) | $-2.05 | $-0.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $4.27 |
| 52-week low | $47.23 | $1.50 |
| Distance from 52-week high | -56.32% | -64.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +181.17% | +171.90% |
| Average volume | 156.28K | 105.22K |
| Shares outstanding | 9.86M | 355.39M |
| Employees | 26 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRUG has outperformed EVO by 49.2 percentage points over the past year.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
DRUG vs EVO FAQ
Which is bigger, Bright Minds Biosciences or Evotec?
Evotec (EVO) is larger, with a market capitalization of $543.75M compared with $533.15M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, DRUG or EVO?
DRUG returned -11.99% over the past 12 months, compared with -61.17% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.